Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Tukysa (tucatinib by Year
Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — International revenues ($M) ($M)
Pfizer Tukysa (tucatinib: $111M in FY2025, up 22.0% from a year earlier.
Where the FY2025 figure comes from
“|| Tukysa | 463 | 480 | (4%) | (4%) | 352 | 389 | (10%) | 111 | 91 | 22% | 18%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — International revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 111 | +22.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 91 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Breakdown
What makes up tukysa (tucatinib
Cite this data
StockData. (2026). Pfizer Tukysa (tucatinib ($M), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tukysa-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.